The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-α and nitric oxide
- 31 July 1995
- journal article
- research article
- Published by Elsevier in International Journal of Immunopharmacology
- Vol. 17 (7), 605-610
- https://doi.org/10.1016/0192-0561(95)00058-a
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoidsEuropean Journal of Immunology, 1995
- Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitorInternational Journal of Immunopharmacology, 1994
- Nitric Oxide Production by Murine Macrophages Is Inhibited by Prolonged Elevation of Cyclic AMPBiochemical and Biophysical Research Communications, 1993
- LPS-Induced Activation of Primed Murine Peritoneal Macrophages Is Modulated by Prostaglandins and Cyclic NucleotidesCellular Immunology, 1993
- The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cellsInternational Journal of Immunopharmacology, 1993
- Nitric oxide and endothelin secretion by brain microvessel endothelial cells: Regulation by cyclic nucleotidesJournal of Cellular Physiology, 1993
- Cloning and Characterization of Inducible Nitric Oxide Synthase from Mouse MacrophagesScience, 1992
- Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.Thorax, 1991
- Regulation of Nitric Oxide Production by Stimulated Rat Kupffer CellsPathobiology, 1991
- Interferon‐γ and tumor necrosis factor induce the L‐arginine‐dependent cytotoxic effector mechanism in murine macrophages*European Journal of Immunology, 1988